Synnovation Therapeutics
Pan-mutant selective PI3K-alpha inhibitor for oncology
- Sector
- Biotech
- Headquarters
- WILMINGTON, DE
- Founded
- 2021
- Latest Form D
- $69.9M, Dec 2023
- Total capital
- $107M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $107M
- 3 Form D · last Dec 2023
- 34 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 40 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 3rd filing$69.9M
- Private capital raisedForm D · SEC · 2nd filing$25M
- Private capital raisedForm D · SEC · 1st filing$12M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- Liangxing WuExecutive Officer, DirectorNamed in SEC Form D filings
- Reid HuberDirectorNamed in SEC Form D filings
- Ting FengDirectorNamed in SEC Form D filings
- Wenqing YaoExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 40- PendingPARP1 InhibitorsUSPTOApplication 18728407
- PendingNRF2 Degrader CompoundsUSPTOApplication PCTUS2025053027
- PendingHeterocyclic Compounds As PARP1 InhibitorsUSPTOApplication 19479040
Show all 40 patent records
- PARP1 InhibitorsMay 22, 2025 · Application 18728407Pending
- NRF2 Degrader CompoundsApplication PCTUS2025053027Pending
- Heterocyclic Compounds As PARP1 InhibitorsApplication 19479040Pending
- Heterocyclic Compounds As PARP1 InhibitorsApplication 19479083Pending
- Heterocyclic Compounds As Modulators Of Tnfa ActivityApplication PCTUS2025047130Pending
- Heterocyclic Compounds As Modulators Of Tnfa ActivityApplication PCTUS2025046571Pending
- Heterocyclic Compounds As Wrn InhibitorsApplication 19162746Pending
- Heterocyclic Compounds As Modulators Of Tnfa ActivityApplication PCTUS2025043164Pending
- Wrn InhibitorsApplication PCTUS2025041932Pending
- Heterocyclic Compounds As Wrn InhibitorsApplication 19149331Pending
- HETEROCYCLIC COMPOUNDS AS MODULATORS OF TNFa ACTIVITYApplication 63845174Pending
- HETEROCYCLIC COMPOUNDS AS MODULATORS OF TNFa ACTIVITYApplication 63820144Pending
- Heterocyclic Compounds As Parg InhibitorsApplication PCTUS2025030160Pending
- Heterocyclic Compounds As NRF2 InhibitorsApplication PCTUS2025028577Pending
- Heterocyclic Compounds As Parg InhibitorsApplication 63795738Pending
- Tricyclic Compounds As Parg InhibitorsApplication PCTUS2025013709Pending
- Heterocyclic Compounds As Parg InhibitorsApplication 63719781Pending
- NRF2 Degrader CompoundsApplication 63713686Pending
- HETEROCYCLIC COMPOUNDS AS MODULATORS OF TNFa ACTIVITYApplication 63697703Pending
- HETEROCYCLIC COMPOUNDS AS MODULATORS OF TNFa ACTIVITYApplication 63695733Pending
- HETEROCYCLIC COMPOUNDS AS MODULATORS OF TNFa ACTIVITYApplication 63686469Pending
- WRN InhibitorsApplication 63683448Pending
- Heterocyclic Compounds As Parg InhibitorsApplication 63681617Pending
- Heterocyclic Compounds As Parg InhibitorsApplication 63651045Pending
- Heterocyclic Compounds As Modulators Of Tnf ActivityApplication PCTUS2026012262Pending
- HETEROCYCLIC COMPOUNDS AS MODULATORS OF TNFa ACTIVITYApplication 63750061Pending
- Heterocyclic Compounds As NRF2 InhibitorsApplication 63646068Pending
- Heterocyclic Compounds As PARP1 InhibitorsApplication PCTUS2024026578Pending
- Heterocyclic Compounds As PARP1 InhibitorsApplication PCTUS2024026586Pending
- Heterocyclic Compounds As Wrn InhibitorsApplication PCTUS2024018967Pending
- Heterocyclic Compounds as WRN InhibitorsApplication 63557025Pending
- Tricyclic Compounds As Parg InhibitorsApplication 63627279Pending
- Heterocyclic Compounds As Wrn InhibitorsApplication PCTUS2024012151Pending
- TRICYCLIC COMPOUNDS AS PI3Ka INHIBITORSApplication 63544512Pending
- Heterocyclic Compounds as WRN InhibitorsApplication 63528938Pending
- Heterocyclic Compounds as PARP1 InhibitorsApplication 63509294Pending
- Heterocyclic Compounds as PARP1 InhibitorsApplication 63521382Pending
- Heterocyclic Compounds As PI3KA InhibitorsApplication PCTUS2023024811Pending
- TRICYCLIC COMPOUNDS AS P13Ka INHIBITORSApplication PCTUS2023023577Pending
- Heterocyclic Compounds as PARP1 InhibitorsApplication 63462569Pending
Related companies, and why
- Kumquat BiosciencesSimilar federal contract value in Biotech · null in contracts
- Maxwell Biosciences, Inc.Similar federal contract value in Biotech · null in contracts
- CURTANA PHARMACEUTICALS INCSimilar federal contract value in Biotech · null in contracts
- Adicet BioSimilar federal contract value in Biotech · null in contracts
- OPSIDIO, LLCSimilar federal contract value in Biotech · null in contracts
- REGENXBIO Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .